Subcutaneous immunotherapy versus sublingual immunotherapy: which is more effective?

Area of Science:

• Allergy and Immunology
• Respiratory Medicine

Background:

• Subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT) are established treatments for allergic rhinitis and asthma.
• Both methods demonstrate disease modification, including reduced new sensitizations and persistent clinical improvement post-treatment.

Purpose of the Study:

• To compare the clinical efficacy and immunologic responses of SCIT and SLIT.
• To identify the need for further head-to-head studies with defined effective doses for both immunotherapy routes.

Main Methods:

• Review of existing meta-analyses comparing SCIT and SLIT against placebo.
• Analysis of limited randomized head-to-head studies.

Main Results:

• Both SCIT and SLIT are effective, with evidence of disease modification.
• Meta-analyses suggest SCIT may be more efficacious than SLIT when compared to placebo.
• Head-to-head studies indicate SCIT often yields greater clinical and immunologic responses.

Conclusions:

• SCIT and SLIT are effective treatments for allergic diseases, offering long-term benefits.
• Further well-defined head-to-head studies are crucial to definitively establish the relative efficacy of SCIT and SLIT.
• SLIT shows a lower incidence of severe systemic reactions compared to SCIT.